

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
2011-002: MSTA	Musculoskeletal Tumor Tissue Acquisition Protocol	Molecular Profiling	SHORE: Dr. Matthew Steensma	researchassist@spectrumhealth.org (616) 391-3050
2012-303: Genetic Outlier	The Identification of Novel Mutations in Outlier Patients	Biobanking	SHORE: Dr. Matthew Steensma	researchassist@spectrumhealth.org (616) 391-3050
2015-051: Pathologic Fractures of the Femur Surgical Trial	A Randomized Trial to Assess Patient Quality of Life and Function After Alternative Surgeries for Pathologic Fractures of the Femur	Treatment	SHORE: Dr. Matthew Steensma	researchassist@spectrumhealth.org (616) 391-3050
2014-295: NF1 Tissue Harvest	A Clinical Translation Approach to Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1	Other	SHORE: Dr. Matthew Steensma	Heidi Chapman <a href="mailto:heidi.chapman@spectrumhealth.org">heidi.chapman@spectrumhealth.org</a> (616) 486-2076
ALTE16C1	Effects of Modern Chemotherapy Regimens on spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma	Other	CRCWM Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
ARST1431	A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temozolomide (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>